Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1097-1108

  Yeh, Shiou Hwei ^a   Wu, Dai Chen ^a   Tsai, Ching Yi ^a   Kuo, Ti Jung ^a   Yu, Wei Che ^a   Chang, Yuan Shau ^a   Chen, Chi Ling ^a   Chang, Ching Fang ^a   Chen, Ding Shinn ^a   Chen, Pei Jer ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; FAS ASSOCIATED PHOSPHATASE 1; PHOSPHATASE; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL PROLIFERATION; CHROMOSOME 4Q; CONTROLLED STUDY; CPG ISLAND; EVALUATION RESEARCH; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; METHYLATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RIBONUCLEASE PROTECTION ASSAY; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 84984586015     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1383     Document Type: Article

References (52)

1. Boige V, Laurent-Puig P, Fouchet P, et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-90.
2. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-33.
3. Chen RJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 1999;19:253-62.
4. Jou YS, Lee CS, Chang YH, et al. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res 2004; 64:3030-6.
5. Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated α-fetoprotein production. Gastroenterology 1996;110:184-92.
6. Yeh SH, Chen PJ, Shau WY, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001;121:699-709.
7. Piao Z, Park C, Park JH, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer 1998;79:356-60.
8. Bando K, Nagai H, Matsumoto S, et al. Identification of a1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1999;25:284-9.
9. Bluteau O, Beaudoin JC, Pasturaud P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34-35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002;21:1225-32.
10. Yeh SH, Lin MW, Lu SF, et al. Allelic loss of chromosome 4q21-23 associates with hepatitis B virus related hepatocarcinogenesis and elevated α-fetoprotein. Hepatology 2004;40:847-54.
11. Hunter T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 1998;94:81-119.
12. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997;9: 193-204.
13. Erdmann KS. The protein tyrosine phosphatase PTP-basophil/basophil-like. Interacting proteins and molecular functions. Eur J Biochem 2003;270:4789-98.
14. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-7.
15. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-50.
16. Liu S, Sugimoto Y, Sorio C, Tecchio C, Lin YC. Function analysis of estrogenically regulated protein tyrosine phosphatase γ (PTPγ) in human breast cancer cell line MCF-7. Oncogene 2004;23:1256-62.
17. Palmer A, Zimmer M, Erdmann KS, et al. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell 2002; 9:725-37.
18. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-6.
19. Saras J, Claesson-Welsh L, Heldin CH, Gonez LJ. Cloning and characterization of PTPL1, a protein tyrosine phosphatase with similarities to cytoskeletal-associated proteins. J Biol Chem 1994;269:24082-9.
20. Banville D, Ahmad S, Stocco R, Shen SH. A novel protein-tyrosine phosphatase with homology to both the cytoskeletal proteins of the band 4.1 family and junction-associated guanylate kinases. J Biol Chem 1994;269:22320-7.
21. Hendriks W, Schepens J, Bachner D, et al. Molecular cloning of a mouse epithelial protein-tyrosine phosphatase with similarities to submembranous proteins. J Cell Biochem 1995;59:418-30.
22. Maekawa K, Imagawa N, Nagamatsu M, Harada S. Molecular cloning of a novel protein-tyrosine phosphatase containing a membrane-binding domain and GLGF repeats. FEBS Lett 1994;337:200-6.
23. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
24. Erdmann KS, Kuhlmann J, Lessmann V, et al. The adenomatous polyposis coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain. Oncogene 2000; 19:3894-901.
25. Kachel N, Erdmann KS, Kremer W, et al. Structure determination and ligand interactions of the PDZ2b domain of PTP-Bas (hPTP1E): splicing-induced modulation of ligand specificity. J Mol Biol 2003;334:143-55.
26. Cuppen E, Gerrits H, Pepers B, Wieringa B, Hendriks W. PDZ motifs in PTP-BL and RIL bind to internal protein segments in the LIM domain protein RIL. Mol Biol Cell 1998;9:671-83.
27. Irie S, Hachiya T, Rabizadeh S, et al. Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-κB activation. FEBS Lett 1999;460:191-8.
28. Maekawa K, Imagawa N, Naito A, Harada S, Yoshie O, Takagi S. Association of protein-tyrosine phosphatase PTP-BAS with the transcription-factor-inhibitory protein IκBα through interaction between the PDZ1 domain and ankyrin repeats. Biochem J 1999;337: 179-84.
29. Gross C, Heumann R, Erdmann KS. The protein kinase C-related kinase PRK2 interacts with the protein tyrosine phosphatase PTP-BL via a novel PDZ domain binding motif. FEBS Lett 2001;496:101-4.
30. Cuppen E, van Ham M, Wansink DG, de Leeuw A, Wieringa B, Hendriks W. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur J Cell Biol 2000;79:283-93.
31. Herrmann L, Dittmar T, Erdmann KS. The protein tyrosine phosphatase PTP-BL associates with the midbody and is involved in the regulation of cytokinesis. Mol Biol Cell 2003;14:230-40.
32. Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92:1159-64.
33. Yu MW, Chang HC, Chen PJ, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002;31:1008-15.
34. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994;54:4188-92.
35. Yoshida S, Harada H, Nagai H, Fukino K, Teramoto A, Emi M. Head-to-head juxtaposition of Fas-associated phosphatase-1 (FAP-1) and c-Jun NH2-terminal kinase 3 (JNK3) genes: genomic structure and seven polymorphisms of the FAP-1 gene. J Hum Genet 2002; 47:614-9.
36. Essers L, Kunze R. A sensitive, quick and semiquantitative LacZ assay for the two-hybrid system. Trends Genet 1996;12:449-50.
37. Irie S, Li Y, Kanki H, et al. Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells. DNA Seq 2001;11:519-26.
38. Murthy KK, Clark K, Fortin Y, Shen SH, Banville D. ZRP-1, azyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E. J Biol Chem 1999;274:20679-87.
39. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54
40. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163: 1101-7.
41. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
42. Lee SH, Shin MS, Lee HS, et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001;32:250-6.
43. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-93.
44. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
45. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: Coleman WB, Tsongalis GJ, editors. The molecular basis of human cancer. Totowa (NJ): Humana Press; 2001. p. 269-346.
46. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003;23:3623-35.
47. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58:1741-9.
48. Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol 2001; 158:1335-44.
49. Bompard G, Puech C, Prebois C, Vignon F, Freiss G. Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. J Biol Chem 2002;277:47861-9.
50. Nakamoto Y, Kaneko S. Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 2003;3: 537-44.
51. Masaki T, Okada M, Shiratori Y, et al. pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 1998;27:1257-64.
52. Ito Y, Kawakatsu H, Takeda T, et al. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J Hepatol 2001;35:68-73.